Skip to main content
Clinical Trials/NCT02078258
NCT02078258
Completed
Not Applicable

Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents: A Randomized Controlled Trial

Hunan Normal University1 site in 1 country45 target enrollmentSeptember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depressive Disorder, Single Episode, Unspecified
Sponsor
Hunan Normal University
Enrollment
45
Locations
1
Primary Endpoint
Changes in depressive symptom number
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

In this study, we test whether a two-week 8-session neutral attention bias modification (ABM) training and a two-week 4-session positive ABM could reduce depressive symptoms relative to placebo controls in adolescents with major depressive disorder at posttraining and follow-ups during one year.

Detailed Description

Depression is a common health problem in adolescents. Negative attentional bias has been theorized to play a critical role in the onset and maintenance of depression, suggesting that reduction of such biases may treat symptoms of depression. Recent studies have shown that attention bias modification(ABM) training could reduce depressive symptoms in both dysphoria and previously depressed adult patients.To test the effectiveness of ABM training on the treatment of depressive symptoms in depressed adolescents, we designed a randomized, double-blind, placebo controlled trial in adolescents with major depressive disorder(MDD).

Registry
clinicaltrials.gov
Start Date
September 2012
End Date
July 2015
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hunan Normal University
Responsible Party
Principal Investigator
Principal Investigator

Wenhui Yang

Department of Psychology

Hunan Normal University

Eligibility Criteria

Inclusion Criteria

  • Meet the major depression disorder's criteria

Exclusion Criteria

  • bipolar disorder, schizophrenia or organic mental disorder;
  • any concurrent psychotherapy;
  • any concurrent psychotropic medication.

Outcomes

Primary Outcomes

Changes in depressive symptom number

Time Frame: baseline, 7-week, 6-month follow-up

Depressive symptom accounts measured by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children.

Changes in depressive severity

Time Frame: baseline, 7-week, 6-month follow-up

depressive severity measured by the construct interview of the Schedule for Affective Disorders and Schizophrenia for School-Age Children(K-SADS)

Secondary Outcomes

  • Diagnostic status of major depressive disorder(baseline, 7-week, 6-month follow-up)
  • Change of Self-report symptoms(baseline, 7-week, 6-, 12-month follow-up)

Study Sites (1)

Loading locations...

Similar Trials